Showing 1 - 10 results of 10 for search 'Gerald S. Falchook', query time: 0.04s Refine Results
  1. 1
    Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review

    Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review by Kavanya Feustel, Gerald S. Falchook

    Published 2022-08-01
    Get full text
    Article
  2. 2
    B7-H3 Inhibitors in Oncology Clinical Trials: A Review

    B7-H3 Inhibitors in Oncology Clinical Trials: A Review by Kavanya Feustel, Jared Martin, Gerald S. Falchook

    Published 2024-02-01
    Get full text
    Article
  3. 3
    Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers

    Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers by Martin V. Nguyen, Lydia Loof, Gerald S. Falchook

    Published 2020-02-01
    Get full text
    Article
  4. 4
    Extracellular Signal-Regulated Kinase (ERK) Inhibitors in Oncology Clinical Trials

    Extracellular Signal-Regulated Kinase (ERK) Inhibitors in Oncology Clinical Trials by Haelee M Chin, David K Lai, Gerald S Falchook

    Published 2019-02-01
    Get full text
    Article
  5. 5
    Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose

    Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose by Wenyuan Xiong, Manja Friese‐Hamim, Andreas Johne, Christopher Stroh, Manfred Klevesath, Gerald S. Falchook, David S. Hong, Pascal Girard, Samer El Bawab

    Published 2021-05-01
    Get full text
    Article
  6. 6
    PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

    PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. by Filip Janku, J Jack Lee, Apostolia M Tsimberidou, David S Hong, Aung Naing, Gerald S Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido-Laguna, Razelle Kurzrock

    Published 2011-01-01
    Get full text
    Article
  7. 7
    Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

    Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine by Apostolia-Maria Tsimberidou, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Filip Janku, Aung Naing, Siqing Fu, Sarina Piha-Paul, Carrie Cartwright, Russell R. Broaddus, Graciela M. Nogueras Gonzalez, Patrick Hwu, Razelle Kurzrock

    Published 2019-12-01
    Get full text
    Article
  8. 8
    736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies

    736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies by Mario Sznol, Harriet Kluger, Igor Puzanov, Gerald S Falchook, Ryan Sullivan, Matthew H Taylor, Justin C Moser, Aaron M Ring, Virginia E Paton, David Chonzi, Brage Garofalo, Mark Sonnemann, Hirdesh Uppal, Jeremy Barton, Beatrice Y McQueen

    Published 2023-11-01
    Article
  9. 9
    759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors

    759 ADPORT-601 (TT-10–101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors by Lawrence Fong, Sumit Subudhi, Gerald S Falchook, Russell Pachynski, Anthony El-Khoueiry, Ian Walters, Robert Krämer, Sushant Kumar, Kasim Mookhtiar, Justin Fairchild, Mohamad A Salkeni, Jaspreet Grewal, William Tester, Samik Upadhaya, Ana Rosa Saez Ibanez, Desa Rae Stanton-Pastore

    Published 2023-11-01
    Article
  10. 10
    Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

    Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors by Filip Janku, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Aung Naing, Gerald S. Falchook, Apostolia M. Tsimberidou, Vanda M. Stepanek, Stacy L. Moulder, J. Jack Lee, Rajyalakshmi Luthra, Ralph G. Zinner, Russell R. Broaddus, Jennifer J. Wheler, Razelle Kurzrock

    Published 2014-01-01
    Get full text
    Article

Search Tools: